Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Invested Capital (2022 - 2025)

Historic Invested Capital for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $5.2 million.

  • 60 Degrees Pharmaceuticals' Invested Capital fell 2063.45% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 2063.45%. This contributed to the annual value of $4.7 million for FY2024, which is 3418.01% down from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Invested Capital stood at $5.2 million for Q3 2025, which was down 2063.45% from $3.1 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Invested Capital high stood at $8.7 million for Q3 2023, and its period low was -$22.7 million during Q4 2022.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Invested Capital value was $4.1 million (recorded in 2024), while the average stood at -$2.7 million.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Invested Capital soared by 40064.79% in 2024, and later tumbled by 3935.31% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Invested Capital (Quarter) stood at -$22.7 million in 2022, then skyrocketed by 131.36% to $7.1 million in 2023, then crashed by 34.18% to $4.7 million in 2024, then rose by 11.78% to $5.2 million in 2025.
  • Its Invested Capital was $5.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $4.7 million in Q1 2025.